tau protein
C2N’s PrecivityAD2 Blood Test Wins Expanded FDA Clearance
The FDA announced on August 20 that it has cleared C2N Diagnostics’ PrecivityAD2 blood test for use in adults as young as 40 who are experiencing signs of cognitive impairment, expanding its authorized use below the 50-and-older threshold the test previously carried. The clearance was announced not by C2N itself but by the Alzheimer’s Drug…
